Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).

EClinicalMedicine（2023）

引用 0|浏览45

暂无评分

摘要

This study was supported by INMI "Lazzaro Spallanzani" Ricerca Corrente Linea 1 on emerging and reemerging infections, funded by Italian Ministry of Health.

查看译文

关键词

Interleukin-6 receptor inhibitors,Randomized clinical trial,SARS-CoV-2 infection,Sarilumab,Severe COVID-19 pneumonia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要